Table 4.
Oral and skin-related side effects of AstraZeneca COVID-19 vaccine among European healthcare workers, February–March 2021.
| Variable | Outcome | <35 Years-Old | 35–49 Years-Old | >49 Years-Old | Total | Sig. 1 |
|---|---|---|---|---|---|---|
| Solicited Oral SE | Ulcers/Blisters/Vesicles | 4 (7.8%) | 3 (13%) | 0 (0%) | 7 (7.6%) | 0.423 |
| White/Red Plaque | 1 (2%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 1.000 | |
| Halitosis | 1 (2%) | 0 (0%) | 2 (11.1%) | 3 (3.3%) | 0.147 | |
| Bleeding Gingiva | 2 (3.9%) | 1 (4.3%) | 0 (0%) | 3 (3.3%) | 1.000 | |
| Swollen Lips | 1 (2%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 1.000 | |
| Unsolicited Oral SE | Taste alterations | 3 (5.9%) | 1 (4.3%) | 1 (5.6%) | 5 (5.4%) | 1.000 |
| Onset | 1–3 days | 12 (100%) | 3 (42.9%) | 4 (100%) | 19 (82.6%) | 0.005 |
| Within 1st week | 0 (0%) | 3 (42.9%) | 0 (0%) | 3 (13%) | ||
| Within 4th week | 0 (0%) | 1 (14.3%) | 0 (0%) | 1 (4.3%) | ||
| Total | 9 (17.6%) | 5 (21.7%) | 2 (11.1%) | 16 (17.4%) | 0.654 | |
| Oral SE Location | Lips | 0 (0%) | 1 (4.3%) | 0 (0%) | 1 (1.1%) | 0.446 |
| Labial/Buccal Mucosa | 2 (3.9%) | 2 (8.7%) | 0 (0%) | 4 (4.3%) | 0.506 | |
| Tongue | 2 (3.9%) | 0 (0%) | 0 (0%) | 2 (2.2%) | 1.000 | |
| Total Oral SE | (0–5) | 0.24 ± 0.55 | 0.22 ± 0.42 | 0.17 ± 0.51 | 0.22 ± 0.51 | 0.739 |
| Skin-related SE | Skin Rash | 2 (3.9%) | 1 (4.3%) | 1 (5.6%) | 4 (4.3%) | 1.000 |
1 Chi-squared test, Fisher’s exact test and Kruskal–Wallis test were used with a significance level of <0.05.